CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and rolled therapeutic products and providing them to people in more than 100 countries. The line of treatments includes products to treat bleeding disorders such as hemophilia and von Willebrand disease; Primary immunodeficiency (PIDD); Genetic angioedema; inherited respiratory disease; and neurological disorders in some markets. The company's products are also used in heart surgery, organ transplantation, burn treatment and the prevention of hemolytry diseases in newborns. CSL Behring is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emile von Behring, and Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004. CSL Behring Parent Company, CSL Ltd (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Victoria, Australia. As part of global harmonization, the CSL Behring brand was founded in 2007. The company, formerly known as ZLB Behring, dates back to 1904, when Behringwerke was founded in Germany by Emile von Behring, the first Nobel Prize winner in medicine as an inventor of serum or serum treatment. CSL Behring operates Plasma CSL, one of the largest plasma collection networks in the world. It has more than 12,000 employees, and more than 270 plasma collection centers covering China, the United States and Europe.